On February 12, 2018, Alkahest, a privately-held clinical-stage company developing treatments for age-related diseases announced that they had received funding from the Michal J. Fox Foundation for Parkinson’s Reseasrch (MJFF). Alkahest has an emphasis on neurodegeneration and cognitive dysfunction, which they consider current key medical challenges. The Alkahest pipeline includes novel products based on factors present in healthy plasma.
Preclinical studies have shown that the plasma-derived product, GRF6019, developed by Grifols (Barcelona) affects motor and cognitive function directly. GRF6019 has been optimized for clinical use and does not require blood-type-matching. The grant from MJFF to Alkahest is to fund a clinical trial of GRF6019/
"The award by The Michael J. Fox Foundation provides important recognition for Alkahest's novel approach using plasma-derived products to treat age-related neurodegenerative diseases, including Parkinson's disease," said Karoly Nikolich, Ph.D., President and Chief Executive Officer of Alkahest Inc. "We are committed to the advancement of novel therapeutics that can have a positive impact in the lives of Parkinson's disease patients."
"Our Foundation funds novel approaches to slow or stop Parkinson's progression, the greatest unmet need for the millions living with this disease," said Brian Fiske, Ph.D., MJFF Senior Vice President of Research Programs. "We are excited to support Alkahest in testing the potential of GRF6019."Next Story